LDH elevation

News alerts, weekly reports and conference planners

Entrez ID:

3939; 3945

Related biomarkers:

Expression

Others

‹

›

LDH elevation	Melanoma	LDH elevation	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
LDH elevation	Diffuse Large B Cell Lymphoma	LDH elevation	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
LDH elevation	Melanoma	LDH elevation	Melanoma	PD-L1 inhibitor Resistant: B - Late Trials PD-L1 inhibitor Resistant : B	PD-L1 inhibitor Resistant: B - Late Trials PD-L1 inhibitor Resistant : B
LDH elevation	Diffuse Large B Cell Lymphoma	LDH elevation	Diffuse Large B Cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
LDH elevation	Burkitt Lymphoma	LDH elevation	Burkitt Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
LDH elevation	Gastric Cancer	LDH elevation	Gastric Cancer	ramucirumab Resistant: C3 – Early Trials ramucirumab Resistant : C3	ramucirumab Resistant: C3 – Early Trials ramucirumab Resistant : C3
LDH elevation	Multiple Myeloma	LDH elevation	Multiple Myeloma	lenalidomide + bortezomib Sensitive: C3 – Early Trials lenalidomide + bortezomib Sensitive : C3	lenalidomide + bortezomib Sensitive: C3 – Early Trials lenalidomide + bortezomib Sensitive : C3
LDH elevation	Marginal Zone Lymphoma	LDH elevation	Marginal Zone Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
LDH elevation	Melanoma	LDH elevation	Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
LDH elevation	Melanoma	LDH elevation	Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
LDH elevation	Diffuse Large B Cell Lymphoma	LDH elevation	Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Resistant: C3 – Early Trials tisagenlecleucel-T Resistant : C3	tisagenlecleucel-T Resistant: C3 – Early Trials tisagenlecleucel-T Resistant : C3
LDH elevation	Follicular Lymphoma	LDH elevation	Follicular Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
LDH elevation	Uveal Melanoma	LDH elevation	Uveal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
LDH elevation	Uveal Melanoma	LDH elevation	Uveal Melanoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
LDH elevation	Triple Negative Breast Cancer	LDH elevation	Triple Negative Breast Cancer	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
LDH elevation	HER2 Positive Breast Cancer	LDH elevation	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Resistant: C3 – Early Trials ado-trastuzumab emtansine Resistant : C3	ado-trastuzumab emtansine Resistant: C3 – Early Trials ado-trastuzumab emtansine Resistant : C3
LDH elevation	Melanoma	LDH elevation	Melanoma	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
LDH elevation	Melanoma	LDH elevation	Melanoma	camrelizumab + rivoceranib Resistant: C3 – Early Trials camrelizumab + rivoceranib Resistant : C3	camrelizumab + rivoceranib Resistant: C3 – Early Trials camrelizumab + rivoceranib Resistant : C3
LDH elevation	Renal Cell Carcinoma	LDH elevation	Renal Cell Carcinoma	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
LDH elevation	Lymphoma	LDH elevation	Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
LDH elevation	Diffuse Large B Cell Lymphoma	LDH elevation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
LDH elevation	Melanoma	LDH elevation	Melanoma	cemiplimab-rwlc + REGN3767 Sensitive: C3 – Early Trials cemiplimab-rwlc + REGN3767 Sensitive : C3	cemiplimab-rwlc + REGN3767 Sensitive: C3 – Early Trials cemiplimab-rwlc + REGN3767 Sensitive : C3
LDH elevation	HER2 Positive Breast Cancer	LDH elevation	HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
LDH elevation	Melanoma	LDH elevation	Melanoma	nivolumab + IO102-IO103 Sensitive: C3 – Early Trials nivolumab + IO102-IO103 Sensitive : C3	nivolumab + IO102-IO103 Sensitive: C3 – Early Trials nivolumab + IO102-IO103 Sensitive : C3
LDH elevation	Non-Hodgkin’s Lymphoma	LDH elevation	Non-Hodgkin’s Lymphoma	ARI-0001 Resistant: C3 – Early Trials ARI-0001 Resistant : C3	ARI-0001 Resistant: C3 – Early Trials ARI-0001 Resistant : C3
LDH elevation	Renal Cell Carcinoma	LDH elevation	Renal Cell Carcinoma	axitinib Resistant: C3 – Early Trials axitinib Resistant : C3	axitinib Resistant: C3 – Early Trials axitinib Resistant : C3
LDH elevation	Esophageal Squamous Cell Carcinoma	LDH elevation	Esophageal Squamous Cell Carcinoma	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3
LDH elevation	Marginal Zone Lymphoma	LDH elevation	Marginal Zone Lymphoma	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3

LDH elevation

Associations